Project Grant HT94252310277
Award Date
4/1/23
Completion Date
3/31/26
Dollars Obligated
$378K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
This Project Grant from the Defense Health Agency provides $494,811 to the University of Cambridge under the Military Medical Research and Development program (CFDA 12.420) from April 1, 2023 to March 31, 2026. The grant funds research to elucidate and target clonal lineages influencing resistance to therapy in distinct mutational subtypes of high-grade ovarian serous carcinoma. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to...
The University of Cambridge will receive $439,922 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program. The grant will fund research from September 2022 through September 2025 to dissect ovarian cancer tumor-immune microenvironments through 3D in situ molecular profiling. The Military Medical Research and Development program aims to transform military and public health through innovative medical research...
The University of Cambridge received a $1,996,828.00 four-year Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research to develop predictive models for treatment response, early relapse, and survival in breast cancer across molecular subtypes. The University will leverage multi-modal data integration techniques to explore early signals of later metastatic recurrence. This research aims to...
The University of Cambridge received a $824,548 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding the role of hypoxia in vasculogenic mimicry, response to therapy, and metastasis. This 3-year grant awarded on May 1, 2024 will support basic, translational, and clinical research to advance scientific understanding and develop new treatments in areas such as cancer, neurological...
The University of Cambridge received a $4,598,677 Project Grant from the Defense Health Agency to conduct research under the Military Medical Research and Development program (CFDA 12.420). The research aims to use multi-modal data integration across breast cancer molecular subtypes to develop predictors of treatment response, early relapse, and survival, as well as explore early signals of later metastatic recurrence. The 4-year grant, which began on September 1, 2023, leverages the...
The University of Cambridge received a $842,452 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on May 1, 2024. The grant supports research to decode the mechanisms of genomic instability in triple-negative breast cancer (TNBC) and how they impact the tissue microenvironment and therapy response at metastatic sites. This 3-year project aims to advance understanding of TNBC biology and identify new therapeutic targets....
The Defense Health Agency awarded a $732,825 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) under the Military Medical Research and Development program (CFDA 12.420) for an extension of an artificial chromosome-based system as a novel delivery strategy for CAR-T cell therapy of ovarian cancer to human lymphocytes. This 3-year project, running from September 1, 2023 to August 31, 2026, aims to develop and validate new treatment approaches for ovarian cancer. As...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...
This $1,014,000 project grant from the Defense Health Agency will fund research into targeted therapeutic opportunities for ovarian clear cell, small cell, and endometrioid carcinomas at President And Fellows of Harvard College from May 1, 2023 to April 30, 2027. The grant falls under the Military Medical Research and Development program, which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical solutions. Through this...
The Department of the Army Medical Command awarded a $1,039,740 project grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to support research titled "NOVEL SYNERGISTIC ATR INHIBITOR COMBINATIONS FOR OVARIAN CANCER THERAPY." The period of performance is from August 1, 2021 to July 31, 2025. This project grant was awarded under the Military Medical Research and Development program (CFDA 12.420). This program supports basic, applied, and advanced biomedical research...